BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The company TKT Europe AB submitted on 4 July 2000 an application for Marketing Authorisation 
to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for  Replagal,  in 
accordance with the centralised procedure falling within the scope of Part A of the Annex to Council 
Regulation No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur: 
Dr. Hans van Bronswijk 
Co-Rapporteur: 
Dr. Per Nilsson 
Scientific Advice: 
The  applicant  received  Scientific  Advice  from  CPMP  on  24  May  1999.  The  Scientific  Advice 
pertained to parts II, III and IV of the dossier.  
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 18 July 2000. 
The  Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on  
27  September  2000.  The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP 
Members on 26 September 2000.  
During  the  meeting  on  14-16  November  2000  the  CPMP  agreed  on  the  consolidated  list  of 
questions  to  be  sent  to  the  applicant.  The  final  consolidated  list  of  questions  was  sent  to  the 
applicant on 16 November 2000.  
The  company  submitted  the  responses  to  the  CPMP  consolidated  list  of  questions  on  24 
November 2000. 
The  summary  report  of  the  inspection  carried  out  at  the  manufacturing  sites  between  28 
November 2000 and 1 December 2000 and on 17 January 2001 was issued on 29 January 2001.  
The Rapporteur circulated the response assessment report on the company’s responses to the list 
of questions to all CPMP Members on 4 January 2001 Part III and IV, 10 January 2001 Part I 
and II.  
During the meeting on 23-25 January 2001, the CPMP agreed on a list of outstanding issues to 
be addressed by the applicant in writing and if necessary during an oral explanation. The list of 
outstanding  issues  was  sent  to  the  applicant  on  25  January  2001.  A  final  revised  list  of 
outstanding issues was sent to the applicant on 2 February 2001.  
The applicant provided written information on these outstanding issues to all CPMP members 
on  5  February  2001.  The  joint  Rapporteur/Co-rapporteur  assessment  report  on  the  written 
responses to the list of outstanding issues was circulated to all CPMP members on 12 February 
2001.  
During  the  CPMP  meeting  on  28  February  2001,  outstanding  quality  and  clinical  issues  were 
addressed by the applicant during an oral explanation before the CPMP.  
1/2 
EMEA 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
• 
During the meeting on 27 - 29 March 2001 the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Replagal on 29 March 2001. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 3 August 2001. 
2/2 
EMEA 2004 
 
 
 
 
 
 
